<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01908686</url>
  </required_header>
  <id_info>
    <org_study_id>1106008625</org_study_id>
    <secondary_id>2R01NS035193-18</secondary_id>
    <nct_id>NCT01908686</nct_id>
  </id_info>
  <brief_title>Pivotal Response Treatment for Children With Autism Spectrum Disorders</brief_title>
  <acronym>PRT</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the application of an evidence-based, manualized&#xD;
      treatment for children with Autism Spectrum Disorder (ASD) (Pivotal Response Treatment, PRT)&#xD;
      to children ages four through six years of age with ASD. Specifically, children will be&#xD;
      randomly assigned to receive either (1) 10 hours per week of intervention services, including&#xD;
      two hours per week of parent education, and eight hours per week of direct&#xD;
      clinician-delivered services, or (2) a treatment as usual control. Intervention will focus on&#xD;
      enhancing the following developmental skills: expressive and receptive language, play, and&#xD;
      social interaction. Outcome measures will address changes in the aforementioned domains&#xD;
      during structured observation and standardized assessment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">March 1, 2020</completion_date>
  <primary_completion_date type="Actual">December 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Social Responsiveness Scale (SRS) Total Score</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impressions Scale (CGI-I)</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Autism Diagnostic Observation Schedule (ADOS) Comparison Score</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aberrant Behavior Checklist (ABC)</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vineland Domain Scores</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Eye Tracking (ET) patterns</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in neural response to social stimuli using fMRI</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Autism Spectrum Disorders</condition>
  <arm_group>
    <arm_group_label>Pivotal Response Training</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pivotal Response Training with children ages 4-35 years of age with an Autism Spectrum Disorder diagnosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Waitlist Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Children in WL will be offered treatment following WL condition.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Pivotal Response Training</intervention_name>
    <description>Behavioral intervention for autism</description>
    <arm_group_label>Pivotal Response Training</arm_group_label>
    <other_name>Pivotal Response Treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Inclusion Criteria:&#xD;
&#xD;
        Participants will:&#xD;
&#xD;
          1. Fit the age requirement: age 4-35&#xD;
&#xD;
          2. Have been diagnosed previously with an ASD and meet criteria for ASD when&#xD;
             characterized by research team.&#xD;
&#xD;
          3. Be in good medical health&#xD;
&#xD;
          4. Be cooperative with testing&#xD;
&#xD;
          5. English is a language spoken in the family&#xD;
&#xD;
          6. Successfully complete an fMRI and EEG scan&#xD;
&#xD;
          7. Full-scale IQ&gt;50&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Exclusion Criteria:&#xD;
&#xD;
        Participants may not have:&#xD;
&#xD;
          1. Any metal or electromagnetic implants, including:&#xD;
&#xD;
               1. Cardiac pacemaker&#xD;
&#xD;
               2. Defibrillator&#xD;
&#xD;
               3. Artificial heart valve&#xD;
&#xD;
               4. Aneurysm clip&#xD;
&#xD;
               5. Cochlear implants&#xD;
&#xD;
               6. Shrapnel&#xD;
&#xD;
               7. Neurostimulators&#xD;
&#xD;
               8. History of metal fragments in eyes or skin&#xD;
&#xD;
          2. Significant hearing loss or other severe sensory impairment&#xD;
&#xD;
          3. A fragile health status.&#xD;
&#xD;
          4. Current use of prescription medications that may affect cognitive processes under&#xD;
             study.&#xD;
&#xD;
          5. A history of significant head trauma or serious brain or psychiatric illness&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Yale Child Study Center - Autism Program</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06512</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 22, 2013</study_first_submitted>
  <study_first_submitted_qc>July 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2013</study_first_posted>
  <last_update_submitted>August 11, 2020</last_update_submitted>
  <last_update_submitted_qc>August 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ASD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autism Spectrum Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

